Science and Enterprise

Category: Joint ventures/collaborations

  • New Process Discovered for Fighting Contact Lens Bacteria

    Researchers at National Jewish Health in Denver, Colorado and the University of Texas Southwestern Medical Center in Dallas, Texas have discovered a new method to fight bacterial infections from contact lenses. The results were published online January 18 in the journal Investigative Ophthalmology and Visual Science (paid subscription required). The problem arises from the interference…

  • Grant Awarded to Company for Kennedy’s Disease Research

    AndroScience Corp., a drug discovery and development company in San Diego, California, said it received a $3.8 million translational research grant to help develop a treatment for spinal and bulbar muscular atrophy, also called Kennedy’s Disease. The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health awarded the grant. The…

  • Device Maker, Heart Institute Fund Cardiac Device Study

    The National Heart, Lung and Blood Institute (NHLBI) and HeartWare, a developer of left ventricular assist devices in Framingham, Massachusetts, have awarded $13.3 million to two universities explore the potential of heart devices for people with heart failure. NHLBI is part of the U.S. National Institutes of Health. The University of Michigan Cardiovascular Center and…

  • Stem Cells Shown to Help Treat Spinal Cord Injuries

    A study by researchers from Case Western Reserve University School of Medicine in Cleveland, Ohio and Athersys Inc., a drug discovery company also in Cleveland, found adult stem cells can help treat spinal cord injuries in rodents. The study tested Athersys’s MultiStem product made of adult (non-embryonic) stem cells obtained from bone marrow. The findings…

  • Theraclone, Pfizer to Partner on Antibody R&D

    Theraclone Sciences Inc., a drug discovery and development company in Seattle, Washington, said today it agreed to a multi-year research and development collaboration with the global pharmaceutical company Pfizer. The deal involves use of Theraclone’s I-STAR technology to discover monoclonal antibodies against up to four targets in the areas of infectious disease and cancer. The…

  • Pharma Company, Institute Seek Alzheimer’s Targets

    Sanford-Burnham Medical Research Institute in La Jolla, California and Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI) in Titusville, New Jersey said today they formed a partnership to discover compounds for Alzheimer’s disease and other psychiatric disorders. Under the agreement, joint Sanford-Burnham and OMJPI teams will identify and validate new targets for drug discovery, leading to compounds suitable for…

  • Research Collaboration Developing More Robust Rice

    A partnership between the Chinese Academy of Agricultural Sciences and the International Rice Research Institute (IRRI) is developing new varieties of rice designed to grow under tough conditions by the poorest farmers. The early results of the project are reported in the January issue of the magazine Rice Today, published by IRRI. Green Super Rice…

  • Gates Grant Awarded for Tuberculosis Genomics Research

    The Infectious Disease Research Institute (IDRI) in Seattle, Washington, said today it received a multi-million dollar grant from the Bill and Melinda Gates Foundation for research in chemical genomics to identify targets and leads in tuberculosis (TB). The project includes access to a large library of compounds at Eli Lilly and Company. The grant aims…

  • Greener Process Developed for Producing Industrial Chemical

    A U.S.-U.K. chemistry and engineering team has developed a more environmentally friendly process for producing benzyl benzoate, a common chemical found in food additives, insecticides, fragrances, and used in other industrial chemical processes. The research was partially funded by the Dow Chemical Company and the findings are published in this week’s issue of the journal…

  • U.K. Partnership to Test Cancer Drug Combinations

    Cancer Research U.K., a London-based organization supporting cancer research, has signed an agreement with the global pharmaceutical company AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials. The trials will be held at hospitals in the U.K. taking part in the Experimental Cancer Medicine Centre (ECMC) Network. The agreement is expected…